This real-world, multicenter study of 82 patients represents the first investigation demonstrating the efficacy and safety of durvalumab as consolidation therapy following definitive CRT for patients with LA-NSCLC in Thailand, primarily focusing on Asian populations where the prevalence of EGFR mutation is higher compared to that in European populations. Here, EGFR is linked to non-small cell lung carcinoma.